Company Monitoring Page for Regeneron

latest headlines for company on cafepharma

Trump Touts Regeneron in Video Message
TheStreet.com
Wed, 10/7/20 - 11:28 pm
Tags:
Regeneron, Donald Trump, politics, antibodies, COVID-19
Regeneron execs go on a whirlwind media tour after Trump takes COVID-19 antibody cocktail
Fierce Pharma
Wed, 10/7/20 - 10:56 am
Tags:
Regeneron, COVID-19, Donald Trump, antibody cocktail
Regeneron CEO Says Trump Receiving Experimental Antibody Treatment Creates ‘Very Tough Situation’
Forbes
Mon, 10/5/20 - 11:47 pm
Tags:
Regeneron, Donald Trump, COVID-19, Pharma CEOs, Leonard Schleifer
Regeneron Shares Jump On FDA Hopes After Trump Receives Its Experimental COVID-19 Treatment
TheStreet.com
Mon, 10/5/20 - 10:54 am
Tags:
Regeneron, Emergency Use Authorization, FDA, COVID-19, Donald Trump
Go or no go? Vaccine panel upstages US approval decisions
EP Vantage
Fri, 10/2/20 - 12:44 pm
Tags:
FDA, vaccines, COVID-19, advisory panel, Eysuvis, Brilinta, Kala Pharmaceuticals, dry eye disease, Regeneron, AstraZeneca, stroke
5 FDA approval decisions to watch in the 4th quarter
BioPharma Dive
Wed, 09/30/20 - 10:45 am
Tags:
FDA, drug approvals, vaccines, Pfizer, Moderna Therapeutics, COVID-19, Regeneron, EB3, ebola virus, Alkermes, ALKS-3831, schizophrenia, bipolar disorder, Bristol-Myers Squibb, liso-cel, non-Hodgkin lymphoma, roxadustat, FibroGen, chronic kidney disease
Regeneron says antibody drug may speed recovery of patients with mild COVID-19
BioPharma Dive
Tue, 09/29/20 - 11:32 pm
Tags:
Regeneron, antibodies, COVID-19
ESMO: Regeneron and Sanofi gun for Libtayo in first-line NSCLC with fresh survival stats
Fierce Pharma
Mon, 09/21/20 - 10:57 am
Tags:
Libtayo, ESMO, Regeneron, Sanofi, non-small cell lung cancer
Sanofi/Regeneron’s Libtayo set for new skin cancer use
Pharmaforum
Fri, 09/18/20 - 10:40 am
Tags:
Sanofi, Regeneron, Libtayo, clinical trials, skin cancer
Sanofi, Regeneron get FDA breakthrough therapy status for Dupixent to treat eosinophilic esophagitis
Pharmaceutical Business Review
Mon, 09/14/20 - 10:50 am
Tags:
Sanofi, Regeneron, Dupixent, FDA, eosinophilic esophagitis, breakthrough status
Novartis says Beovu matched rival Eylea in visual acuity in eye disease
Pharma Live
Mon, 09/14/20 - 10:41 am
Tags:
Novartis, Beovu, Eylea, Regeneron, diabetic macular edema, clinical trials
Sanofi Halts Kevzara Tests for Covid as Drug Fails to Help
Bloomberg
Tue, 09/1/20 - 10:41 am
Tags:
Sanofi, Regeneron, Kevzara, COVID-19, clinical trials
ESC: Amgen chases pediatric use for cholesterol-busting PCSK9 med Repatha
Fierce Pharma
Sun, 08/30/20 - 11:25 pm
Tags:
ESC, Amgen, Repatha, Sanofi, Regeneron, Praluent, cholesterol
Chasing Regeneron, AZ starts trials of its COVID-19 antibody cocktail
Pharmaforum
Tue, 08/25/20 - 10:18 am
Tags:
AstraZeneca, Regeneron, antibody cocktail, clinical trials, COVID-19
Regeneron flashes ‘great advance' in the NEJM for that other cholesterol drug sitting at the FDA
Endpoints
Wed, 08/19/20 - 11:45 pm
Tags:
Regeneron, inclisiran, RNAi, Novartis, New England Journal of Medicine
Regeneron, Roche team up in global deal on Covid-19 antibody cocktail
MedCity News
Wed, 08/19/20 - 11:13 am
Tags:
Roche, Regeneron, COVID-19, antibodies, antibody cocktail
Regeneron's Praluent sidekick nabs speedy FDA review, with February PDUFA date
Fierce Biotech
Wed, 08/12/20 - 10:53 am
Tags:
Regeneron, evicanumab, FDA, Homozygous Familial Hypercholesterolemia
Regeneron profit beats, expects early results from COVID-19 trials in September
Yahoo/Reuters
Wed, 08/5/20 - 10:25 am
Tags:
Regeneron, earnings, COVID-19
Regeneron says antibody cocktail prevents and treats coronavirus in animals
CNBC
Tue, 08/4/20 - 01:13 pm
Tags:
Regeneron, antibodies, COVID-19
Regeneron pairs with BioNTech on melanoma immunotherapy
Pharmaforum
Mon, 08/3/20 - 10:15 am
Tags:
Regeneron, BioNTech, melanoma, Libtayo, vaccines, BNT111, MRNA

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.